PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 635 (xsd:integer)
nif:isString
  • The MOTIVATE 1 (conducted in North America) and MOTIVATE 2 (conducted in Europe, Australia, and the US) phase III clinical trials sought to study the safety and efficacy of maraviroc in multi-drug resistant patients harboring R5 tropic viruses. (MOTIVATE stands for araviroc versus ptimized herapy n iremic ntiretroviral reatment xperienced patients) Results from these trials published in 2008 indicated patients receiving maraviroc (either once or twice daily) plus an optimized background therapy (OBT) showed significant reductions in HIV-1 RNA levels and increases in CD4 cell counts versus patients receiving OBT alone [130,131].
rdf:type